Company intelligence / Profile preview
Seal Rock Therapeutics
Seattle, Washington, United Statessealrocktx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Developing a second-generation ASK1 inhibitor designed to improve safety profile for liver diseases; also working on programs for CNS conditions
- Therapeutic areas
- GastroenterologyImmunologyNeurology
- Modalities
- Small molecule kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Genfit (for liver failure program)
Beyond the preview
Go deeper on Seal Rock Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seal Rock Therapeutics.